Hayat Pharmaceutical Industries Co (AMM:HPIC) Interest Expense: JOD-0.14 Mil (TTM As of Mar. 2026)


AMM:HPIC Hayat Pharmaceutical Industries Co AMM:HPIC
76 GF Score
Price JOD3.20
GF Value JOD2.74
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hayat Pharmaceutical Industries Co Interest Expense?

Hayat Pharmaceutical Industries Co AMM:HPIC 76 Interest Expense is JOD-0.14 Mil as of Mar. 2026. GuruFocus rates AMM:HPIC with a GF Score™ of 76/100 and a GF Value™ of JOD2.74 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Hayat Pharmaceutical Industries Co's interest expense for the three months ended in Mar. 2026 was JOD -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was JOD-0.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Hayat Pharmaceutical Industries Co's Operating Income for the three months ended in Mar. 2026 was JOD 0.14 Mil. Hayat Pharmaceutical Industries Co's Interest Expense for the three months ended in Mar. 2026 was JOD -0.03 Mil. Hayat Pharmaceutical Industries Co's Interest Coverage for the quarter that ended in Mar. 2026 was 4.55. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hayat Pharmaceutical Industries Co  (AMM:HPIC) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hayat Pharmaceutical Industries Co's Interest Expense for the three months ended in Mar. 2026 was JOD-0.03 Mil. Its Operating Income for the three months ended in Mar. 2026 was JOD0.14 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was JOD3.11 Mil.

Hayat Pharmaceutical Industries Co's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*0.141/-0.031
=4.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Hayat Pharmaceutical Industries Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Hayat Pharmaceutical Industries Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hayat Pharmaceutical Industries Co Interest Expense Chart

Hayat Pharmaceutical Industries Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.07 -0.10 -0.15 -0.14

Hayat Pharmaceutical Industries Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.05 -0.02 -0.03
AMM:HPIC
76GF Score
Hayat Pharmaceutical Industries Co AMM:HPIC
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hayat Pharmaceutical Industries Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of JOD-0.14 Mil mean?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a Interest Expense of JOD-0.14 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hayat Pharmaceutical Industries Co and its competitors.
Is Hayat Pharmaceutical Industries Co's Interest Expense too high?
Hayat Pharmaceutical Industries Co's current Interest Expense is JOD-0.14 Mil. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's Interest Expense compare to ZTS and UTHR?
Hayat Pharmaceutical Industries Co's Interest Expense of JOD-0.14 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hayat Pharmaceutical Industries Co and its competitors. Hayat Pharmaceutical Industries Co's current Interest Expense is JOD-0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co (AMM:HPIC) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD2.74, compared to a current price of JOD3.20 — trading 16.8% above its estimated fair value. The current Interest Expense is JOD-0.14 Mil. Hayat Pharmaceutical Industries Co's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current Interest Expense is JOD-0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hayat Pharmaceutical Industries Co (AMM:HPIC) Overvalued in 2026?

Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co stock appears to be overvalued. The current stock price of JOD3.20 is trading 16.8% above its estimated GF Value™ of JOD2.74. GuruFocus considers Hayat Pharmaceutical Industries Co to be Modestly Overvalued.

Key valuation signals for AMM:HPIC:

  • Interest Expense: JOD-0.14 Mil
  • GF Value™: JOD2.74 vs. price of JOD3.20 (16.8% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the AMM:HPIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hayat Pharmaceutical Industries Co Business Description

Address Mohammed Ali Alkurdi St. Al-Rajeeb Amman, 1564 Amman, Amman, JOR, 11118
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
76GF Score

Get the complete analysis for AMM:HPIC

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD3.20
Price
JOD2.74
GF Value